We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01021514
First Posted: November 30, 2009
Last Update Posted: April 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Korea University
  Purpose
Arteriosclerosis is a dynamic inflammatory disorder. Recently, FDG-PET CT is emerging diagnostic tool of non-invasive technique to detect vulnerable atherosclerotic plaque. And there are arising evidence that sRAGE(soluble Receptor for Advanced glycation End Product) is correlated with metabolic risk. So the investigators will investigate association between sRAGE and FDG-PET uptake in large artery in healthy patient.

Condition
sRAGE Level SUV and TBR Levels in FDG PET

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

Resource links provided by NLM:


Further study details as provided by Korea University:

Enrollment: 82
Study Start Date: January 2009
Study Completion Date: November 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Type 2 DM, Healthy control
Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
Type 2 DM, Heatlhy control

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
type 2 DM diagnoed according to critereia of American Diabetes Asociation.
Criteria

Inclusion Criteria:

  • Clinical diagnosis od type 2 DM

Exclusion Criteria:

  • Type 1 DM
  • Gestational Diabetes
  • Severe Liver or Renal disease
  • Diagnosis of cancer
  • Trauma
  • Acute infection or inflammatory disease
  • Acute vasculitis or history of vasculitis
  • Pregnant or Lactating women
  • Dyslipidemia(active state)
  • Cardiovascular disease or history of CVD
  • Chronic obstructive pulmonary disease
  • Any patient by judge of investigator
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01021514


Sponsors and Collaborators
Korea University
Investigators
Principal Investigator: Kyoungmook Choi, MD, PhD Korea University Guro Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Korea University Guro Hopital Endocrinology department, Korea University Guro Hospital
ClinicalTrials.gov Identifier: NCT01021514     History of Changes
Other Study ID Numbers: PET(RAGE)
First Submitted: November 27, 2009
First Posted: November 30, 2009
Last Update Posted: April 6, 2011
Last Verified: April 2011

Keywords provided by Korea University:
sRAGE
SUV
TBR
FDG PET CT
Type 2 DM

Additional relevant MeSH terms:
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action